BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) today reported results from its Phase III 12-month open-label safety and efficacy study evaluating EMBEDA™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules. The results were presented in a poster session (abstract #229) at the American Academy of Pain Medicine’s 25th Annual Meeting in Honolulu, HI. The results showed that EMBEDA™ provided continued pain relief for up to 12 months in opioid-tolerant patients with chronic, moderate to severe, non-malignant pain. Findings also showed that EMBEDA™ was safe and well-tolerated for long-term chronic pain therapy.
